CAR T-cell therapy shows ‘high and durable response rates’ in adults with B-cell ALL

55729

Sumary of CAR T-cell therapy shows ‘high and durable response rates’ in adults with B-cell ALL:

  • Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results..
  • Data from ZUMA-3 trial — presented during the virtual ASCO Annual Meeting — also showed that approximately a quarter of patients treated with the chimeric antigen receptor T-cell therapy experienced grade 3 or greater cytokine release syndrome or neurotoxicity..
  • Kite Pharma/Gilead) — formerly known as KTE-X19 — among adults with relapsed or refractory B-cell ALL, according to Bijal D..
  • “The 1-year overall survival rate for patients with relapsed or refractory B-cell ALL is 26% after first salvage therapy and decreases with subsequent lines of therapy.”.
  • Novel targeted agents have led to improved initial complete response rates, but OS remains less than 8 months or longer depending on whether patients undergo subsequent allogeneic hematopoietic stem cell transplant, Shah said..
  • Brexucabtagene autoleucel, an autologous, gene-edited CAR T-cell therapy, targets the CD19 protein on the surface of cancer cells..
  • The therapy previously received FDA approval for the treatment of adults with relapsed or refractory mantle cell lymphoma..
  • The manufacturer has submitted a supplemental biologics license application to the FDA for the B-cell ALL indication based on results of the phase 1 portion of the ZUMA-3 trial….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close